Last reviewed · How we verify
Placebo of ADC189 tablets
This is a placebo control formulation used in clinical trials and contains no active pharmaceutical ingredient.
At a glance
| Generic name | Placebo of ADC189 tablets |
|---|---|
| Sponsor | Jiaxing AnDiCon Biotech Co.,Ltd |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, this formulation is pharmacologically inert and serves as a control comparator in randomized clinical trials. It allows researchers to distinguish the true therapeutic effects of ADC189 from placebo response and natural disease progression. Placebos are essential for establishing efficacy and safety profiles in phase 3 trials.
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of ADC189 in Children 2-11 Years Old With Influenza (PHASE3)
- ADC189 Tablets on Influenza A Virus Infection/Influenza B Virus Infection (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of ADC189 tablets CI brief — competitive landscape report
- Placebo of ADC189 tablets updates RSS · CI watch RSS
- Jiaxing AnDiCon Biotech Co.,Ltd portfolio CI